Literature DB >> 17894707

Perceptions of facial aesthetics in surgical patients with basal cell carcinoma.

B Essers1, F Nieman, M Prins, N Smeets, H Neumann.   

Abstract

BACKGROUND: Basal cell carcinoma (BCC) is a non-melanoma form of skin cancer that is frequently localized within the cervicofacial area. So far, little research is available on how patients perceive their facial aesthetics after surgical treatment for BCC.
OBJECTIVES: To analyse (i) if there was a statistically significant improvement over time with regard to the perceived facial aesthetics of surgical patients; (ii) if there was a significant difference between primary and recurrent BCC patients; and (iii) between patients who had Mohs micrographic surgery (MMS) or surgical excision (SE). To assess (iv) which baseline perceptions and/or clinical parameters may predict the evaluation of facial aesthetics at 6 months after surgery.
METHODS: Parallel to a clinical trial, a survey was carried out in which patients were asked, by means of a newly developed disease-specific questionnaire, about perceptions with regard to their facial aesthetics before and after surgery.
RESULTS: Aesthetic perceptions of all surgical patients improved over time. There was no statistically significant difference on facial aesthetics between the group with a primary or recurrent BCC and patients treated with MMS or SE. Results also showed that the evaluation of postsurgical facial aesthetics can be predicted by both visibility of the tumour and preoperative perceptions.
CONCLUSION: It is recommended to administer preoperatively a short questionnaire in which perceptions related to facial aesthetics are included. In doing so, physicians will become more familiar with the aesthetic problems patients might have regarding their afflicted facial site. Ultimately, it may help physicians in deciding whether patients will benefit from additional cosmetic procedures after surgery.

Entities:  

Mesh:

Year:  2007        PMID: 17894707     DOI: 10.1111/j.1468-3083.2007.02227.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

1.  Fee comparisons of treatments for nonmelanoma skin cancer in a private practice academic setting.

Authors:  Leslie S Wilson; Mark Pregenzer; Rituparna Basu; Daniel Bertenthal; Jeanette Torres; Maryam Asgari; Mary-Margaret Chren
Journal:  Dermatol Surg       Date:  2011-12-06       Impact factor: 3.398

2.  Patient indications for Mohs micrographic surgery: a clinical practice guideline.

Authors:  C Murray; D Sivajohanathan; T P Hanna; S Bradshaw; N Solish; B Moran; R Hekkenberg; A C Wei; T Petrella
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

3.  Sustained use of an occupational sun safety program in a recreation industry: follow-up to a randomized trial on dissemination strategies.

Authors:  David B Buller; Barbara J Walkosz; Peter A Andersen; Michael D Scott; Gary R Cutter
Journal:  Transl Behav Med       Date:  2015-06-06       Impact factor: 3.046

4.  Periocular basal cell carcinoma results and surgical outcome during a 5-year period in a larger Danish population.

Authors:  Sveina Björk Karlsdóttir; Simon Johannessen; Nikolaj Carsting Bjerrum; Ulrik Frydkjær-Olsen; Søren Leer Blindbæk; Flemming Møller; Camilla Wellejus
Journal:  BMC Ophthalmol       Date:  2022-06-28       Impact factor: 2.086

5.  Effect of an intervention on observed sun protection by vacationers in a randomized controlled trial at North American resorts.

Authors:  David B Buller; Peter A Andersen; Barbara J Walkosz; Michael D Scott; Larry Beck; Gary R Cutter
Journal:  Prev Med       Date:  2017-02-09       Impact factor: 4.018

6.  Rationale, design, samples, and baseline sun protection in a randomized trial on a skin cancer prevention intervention in resort environments.

Authors:  David B Buller; Peter A Andersen; Barbara J Walkosz; Michael D Scott; Larry Beck; Gary R Cutter
Journal:  Contemp Clin Trials       Date:  2015-11-22       Impact factor: 2.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.